The estimated Net Worth of John Richard Pinion is at least $10.4 Milión dollars as of 1 March 2024. Mr. Pinion owns over 4,173 units of Ultragenyx Pharmaceutical stock worth over $5,028,466 and over the last 9 years he sold RARE stock worth over $2,006,926. In addition, he makes $3,370,530 as Chief Quality Officer and Executive Vice President of Translational Sciences at Ultragenyx Pharmaceutical.
John has made over 9 trades of the Ultragenyx Pharmaceutical stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 4,173 units of RARE stock worth $224,340 on 1 March 2024.
The largest trade he's ever made was selling 6,198 units of Ultragenyx Pharmaceutical stock on 1 March 2021 worth over $856,378. On average, John trades about 739 units every 37 days since 2015. As of 1 March 2024 he still owns at least 89,268 units of Ultragenyx Pharmaceutical stock.
You can see the complete history of Mr. Pinion stock trades at the bottom of the page.
John R. Pinion II serves as Chief Quality Officer and Executive Vice President of Translational Sciences of the Company. He served as our Executive Vice President of Analytical Sciences and Research, and between July 2015 and September 2017, as our Chief Quality Operations Officer. Between July 2015 and January 2016, he served as our Senior Vice President of Analytical Sciences and Research. Prior to Ultragenyx, Mr. Pinion served in various roles with increasing responsibilities at Genentech, a pharmaceutical company, between 2005 and June 2015, including his most recent position as the Senior Vice President and Global Head of Quality and Compliance for Roche/Genentech Pharma Technical Operations from October 2009 to July 2015. Mr. Pinion holds a B.S. of Science in Mechanical Engineering from the University of West Virginia.
As the Chief Quality Officer and Executive Vice President of Translational Sciences of Ultragenyx Pharmaceutical, the total compensation of John Pinion at Ultragenyx Pharmaceutical is $3,370,530. There are 2 executives at Ultragenyx Pharmaceutical getting paid more, with Emil Kakkis having the highest compensation of $6,586,480.
John Pinion is 54, he's been the Chief Quality Officer and Executive Vice President of Translational Sciences of Ultragenyx Pharmaceutical since 2017. There are 19 older and 6 younger executives at Ultragenyx Pharmaceutical. The oldest executive at Ultragenyx Pharmaceutical Inc. is William Aliski, 73, who is the Independent Director.
John's mailing address filed with the SEC is 60 Leveroni Ct, Novato, CA 94949, USA.
Over the last 11 years, insiders at Ultragenyx Pharmaceutical have traded over $102,813,606 worth of Ultragenyx Pharmaceutical stock and bought 203,500 units worth $4,623,050 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Llc Fmr a Clay B Siegall. On average, Ultragenyx Pharmaceutical executives and independent directors trade stock every 17 days with the average trade being worth of $573,045. The most recent stock trade was executed by Emil D Kakkis on 3 September 2024, trading 20,000 units of RARE stock currently worth $1,117,000.
ultragenyx is a clinical-stage biotechnology company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies. our company is led by an experienced management team in rare disease therapeutics. recognizing that our primary responsibility is to our patients, we are working with advocacy groups to provide support and outreach to individuals and families affected by these disorders and engage them in the clinical testing process. we are also working with regulatory agencies to design and conduct high quality clinical studies that meet the requirements for approval. we are creating an improved model for successful rare disease d
Ultragenyx Pharmaceutical executives and other stock owners filed with the SEC include: